Remicade biosimilar – Renflexis receives approval from US regulators

US regulators have approved Renflexis, a biosimilar referencing Johnson & Johnson’s tumour necrosis factor (TNF) blocker Remicade (infliximab), across all eligible indications. Physicians will now be able to prescribe the drug for reducing signs and symptoms in patients with adult and paediatric Crohn’s disease, adult ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, and

Continue Reading